病毒性肝炎高胆红素血症应用前列地尔注射液治疗的临床研究(1)
[摘要] 目的 研究病毒性肝炎高膽红素血症应用前列地尔注射液治疗的临床疗效。方法 回顾性方便抽取50例于2016年1月—2018年12月至该接受治疗的病毒性肝炎高胆红素血症患者作为该次研究对象，使用双盲法将全部患者分为A组和B组，每组25例。其中，A组给予临床常规治疗方法，B组在A组的治疗基础上加用前列地尔治疗，观察对比两组患者的临床治疗效果、治疗前后的凝血酶原时间、丙氨酸转氨酶、总胆红素，以及不良反应发生率。 结果 A组治疗总有效率为76.00%，低于B组治疗总有效率的96.00%(χ2=4.153，P=0.042);对比两组治疗前的凝血酶原时间、丙氨酸转氨酶、总胆红素水平发现，差异无统计学意义(P>0.05);对比两组治疗后的凝血酶原时间、丙氨酸转氨酶、总胆红素评分发现，相较于A组，B组各项指标降低更显着，差异有统计学意义(P<0.05)。A组不良反应发生率为16.00%，高于B组不良反应发生率的4.00%，组间差异无统计学意义(χ2=2.000，P>0.05)。 结论 对病毒性肝炎高胆红素血症患者给予前列地尔注射液进行治疗，能在提高临床治疗效果的同时，改善其凝血酶原时间、丙氨酸转氨酶以及总胆红素状态，同时还能够降低不良反应发生率，具有较高的实际应用价值，值得推广使用。
[关键词] 病毒性肝炎高胆红素血症;前列地尔注射液;临床治疗效果研究
[中图分类号] R51 [文献标识码] A [文章编号] 1674-0742(2019)06(b)-0132-03
[Abstract] Objective To study the clinical efficacy of prostaglandin injection in the treatment of viral hepatitis hyperbilirubinemia. Methods A retrospective study of 50 patients with viral hepatitis hyperbilirubinemia who were convenient selected and treated from January 2016 to December 2018 was used as the study group. All patients were divided into group A and group B by double-blind method， 25 cases in each group. Among them， group A was given clinical routine treatment， group B was treated with alprostadil in the treatment of group A， and the clinical treatment effect of the two groups was compared， prothrombin time before and after treatment， alanine aminotransferase， total Bilirubin， as well as the incidence of adverse reactions. Results The total effective rate was 76.00% in group A， which was lower than the total effective rate of 96.00% in group B，(χ2=4.153， P=0.042). The prothrombin time， alanine aminotransferase and total gallbladder before treatment were compared between the two groups. The level of erythropoietin was found to be(P>0.05)， and the comparison was not statistically significant. The prothrombin time， alanine aminotransferase and total bilirubin scores after treatment were compared between the two groups. More significantly， the difference was statistically significant(P<0.05). The incidence of adverse reactions in group A was 16.00%， which was higher than the incidence of adverse reactions in group B of 4.00%， There was no statistically significant difference between groups(χ2=2.000， P>0.05). Conclusion The administration of alprostadil in patients with viral hepatitis hyperbilirubinemia can improve the clinical therapeutic effect and improve the prothrombin time， alanine aminotransferase and total bilirubin status. It can also reduce the incidence of adverse reactions， has a high practical value， and is worthy of promotion., 百拇医药(董淦功)
[关键词] 病毒性肝炎高胆红素血症;前列地尔注射液;临床治疗效果研究
[中图分类号] R51 [文献标识码] A [文章编号] 1674-0742(2019)06(b)-0132-03
[Abstract] Objective To study the clinical efficacy of prostaglandin injection in the treatment of viral hepatitis hyperbilirubinemia. Methods A retrospective study of 50 patients with viral hepatitis hyperbilirubinemia who were convenient selected and treated from January 2016 to December 2018 was used as the study group. All patients were divided into group A and group B by double-blind method， 25 cases in each group. Among them， group A was given clinical routine treatment， group B was treated with alprostadil in the treatment of group A， and the clinical treatment effect of the two groups was compared， prothrombin time before and after treatment， alanine aminotransferase， total Bilirubin， as well as the incidence of adverse reactions. Results The total effective rate was 76.00% in group A， which was lower than the total effective rate of 96.00% in group B，(χ2=4.153， P=0.042). The prothrombin time， alanine aminotransferase and total gallbladder before treatment were compared between the two groups. The level of erythropoietin was found to be(P>0.05)， and the comparison was not statistically significant. The prothrombin time， alanine aminotransferase and total bilirubin scores after treatment were compared between the two groups. More significantly， the difference was statistically significant(P<0.05). The incidence of adverse reactions in group A was 16.00%， which was higher than the incidence of adverse reactions in group B of 4.00%， There was no statistically significant difference between groups(χ2=2.000， P>0.05). Conclusion The administration of alprostadil in patients with viral hepatitis hyperbilirubinemia can improve the clinical therapeutic effect and improve the prothrombin time， alanine aminotransferase and total bilirubin status. It can also reduce the incidence of adverse reactions， has a high practical value， and is worthy of promotion., 百拇医药(董淦功)